These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16411420)

  • 1. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis.
    van Marion AM; Auwerda JJ; Minnema MC; van Oosterom R; Adelmeijer J; de Groot PG; Leebeek FW; Sonneveld P; Lokhorst HM; Lisman T
    Thromb Haemost; 2005 Dec; 94(6):1341-3. PubMed ID: 16411420
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.
    Minnema MC; Breitkreutz I; Auwerda JJ; van der Holt B; Cremer FW; van Marion AM; Westveer PH; Sonneveld P; Goldschmidt H; Lokhorst HM
    Leukemia; 2004 Dec; 18(12):2044-6. PubMed ID: 15470485
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
    Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Deep vein thrombosis and pulmonary embolism in a patient with multiple myeloma treated with thalidomide and dexamethasone].
    Miyazawa Y; Irisawa H; Uchiumi H; Saitoh T; Handa H; Matsushima T; Tsukamoto N; Karasawa M; Murakami H; Nojima Y
    Rinsho Ketsueki; 2006 Jul; 47(7):656-60. PubMed ID: 16910577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
    Zangari M; Saghafifar F; Anaissie E; Badros A; Desikan R; Fassas A; Mehta P; Morris C; Toor A; Whitfield D; Siegel E; Barlogie B; Fink L; Tricot G
    Blood Coagul Fibrinolysis; 2002 Apr; 13(3):187-92. PubMed ID: 11943931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment.
    Minnema MC; Fijnheer R; De Groot PG; Lokhorst HM
    J Thromb Haemost; 2003 Mar; 1(3):445-9. PubMed ID: 12871448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.
    Cavo M; Zamagni E; Cellini C; Tosi P; Cangini D; Cini M; Valdrè L; Palareti G; Masini L; Tura S; Baccarani M
    Blood; 2002 Sep; 100(6):2272-3. PubMed ID: 12229885
    [No Abstract]   [Full Text] [Related]  

  • 8. Thrombosis in multiple myeloma.
    Zangari M; Elice F; Fink L; Tricot G
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):307-15. PubMed ID: 17338651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis.
    Rus C; Bazzan M; Palumbo A; Bringhen S; Boccadoro M
    J Thromb Haemost; 2004 Nov; 2(11):2063-5. PubMed ID: 15550053
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
    Ciepłuch H; Baran W; Hellmann A
    Med Sci Monit; 2002 Apr; 8(4):PI31-6. PubMed ID: 11951079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
    Palumbo A; Cavo M; Bringhen S; Zamagni E; Romano A; Patriarca F; Rossi D; Gentilini F; Crippa C; Galli M; Nozzoli C; Ria R; Marasca R; Montefusco V; Baldini L; Elice F; Callea V; Pulini S; Carella AM; Zambello R; Benevolo G; Magarotto V; Tacchetti P; Pescosta N; Cellini C; Polloni C; Evangelista A; Caravita T; Morabito F; Offidani M; Tosi P; Boccadoro M
    J Clin Oncol; 2011 Mar; 29(8):986-93. PubMed ID: 21282540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide for the treatment of leptomeningeal multiple myeloma.
    Yutaka H; Mariko Y; Shinichiro O; Kunihiko M; Yusuke T; Yasuo I
    Eur J Haematol; 2006 Apr; 76(4):358-9. PubMed ID: 16519710
    [No Abstract]   [Full Text] [Related]  

  • 13. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma.
    Dimopoulos MA; Hamilos G; Zomas A; Gika D; Efstathiou E; Grigoraki V; Poziopoulos C; Xilouri I; Zorzou MP; Anagnostopoulos N; Anagnostopoulos A
    Hematol J; 2004; 5(2):112-7. PubMed ID: 15048060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients.
    Zangari M; Barlogie B; Cavallo F; Bolejack V; Fink L; Tricot G
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):595-8. PubMed ID: 17890944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel approaches to the management of myeloma.
    Rajkumar SV
    Oncology (Williston Park); 2005 Apr; 19(5):621-5. PubMed ID: 15948290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
    Chim CS
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
    [No Abstract]   [Full Text] [Related]  

  • 17. Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma.
    Maharaj S; Chang S; Seegobin K; Serrano-Santiago I; Zuberi L
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):585-591. PubMed ID: 28508703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide.
    Offidani M; Corvatta L; Polloni C; Gentili S; Brioni A; Visani G; Galieni P; Brunori M; Alesiani F; Catarini M; Centurioni R; Samori A; Blasi N; Ferranti M; Fraticelli P; Mele A; Rizzi R; Larocca F; Leoni P
    Leuk Lymphoma; 2011 May; 52(5):776-85. PubMed ID: 21338282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombotic complications in multiple myeloma: a report of three cases and review of the literature.
    Ipek Y; Fehmi H; Sevgi BK; Deniz S
    J Thromb Thrombolysis; 2012 Feb; 33(2):197-201. PubMed ID: 21904842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimising bortezomib in newly diagnosed multiple myeloma.
    Rajkumar SV
    Lancet Oncol; 2010 Oct; 11(10):909-10. PubMed ID: 20739219
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.